A 62-year-old woman with metastatic renal cell carcinoma progresses on sunitinib after 8 months of treatment. She has good performance status and no significant comorbidities. What is the drug of choice for second-line therapy?
A. Nivolumab
B. Cabozantinib
C. Sorafenib
D. Axitinib
Explanation
Second-Line Therapy After TKI Progression in RCC
Key Point
Cabozantinib is the preferred second-line agent for metastatic renal cell carcinoma (mRCC) progressing on first-line VEGFR-TKI therapy (e.g., sunitinib), based on superior PFS and OS data from the METEOR trial (NCCN 2023–2024, ESMO, ASCO guidelines).
Why Cabozantinib?
Cabozantinib is a multi-kinase inhibitor targeting VEGFR, MET, and AXL — pathways implicated in resistance to sunitinib. The METEOR trial (Choueiri et al., NEJM 2015) demonstrated:
Median PFS: 7.4 months vs. 3.8 months (everolimus) — HR 0.58
Median OS: 21.4 months vs. 16.5 months — HR 0.66
Significant improvement in objective response rate (ORR: 21% vs. 5%)
This OS benefit established cabozantinib as a Category 1 preferred second-line option in NCCN guidelines for patients progressing on prior anti-VEGF therapy.
Comparison of Second-Line Options
Table
Agent
Mechanism
Key Trial
Median PFS
Guideline Status
Cabozantinib
VEGFR/MET/AXL TKI
METEOR
7.4 months
Preferred (Category 1)
Nivolumab
PD-1 checkpoint inhibitor
CheckMate 025
4.6 months
Preferred (Category 1)
Axitinib
VEGFR-selective TKI
AXIS
6.7 months
Acceptable alternative
Sorafenib
VEGFR/BRAF/c-KIT TKI
Historical
5.5 months
No longer preferred
Why Not the Other Options?
Sorafenib (A): Historically used post-sunitinib but now considered outdated; inferior PFS/OS compared to cabozantinib and nivolumab. Not a preferred agent per current NCCN/ESMO 2023–2024 guidelines.
Nivolumab (B): Also a Category 1 preferred option (CheckMate 025 showed OS benefit over everolimus), but cabozantinib is generally favored when prior immunotherapy has not been used and in patients with intermediate/poor risk features where TKI re-challenge is appropriate.
Axitinib (D): Acceptable second-line option (AXIS trial), but does not demonstrate OS benefit over comparators; less preferred than cabozantinib in current guidelines.
Clinical Pearl
Per NCCN 2023–2024 and ESMO guidelines, cabozantinib and nivolumab are both Category 1 preferred second-line agents after VEGFR-TKI failure. Cabozantinib is particularly favored in patients with good performance status (as in this vignette) due to its dual PFS and OS benefit in the METEOR trial.
Reference: Choueiri TK et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. NEJM 2015; NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 2024.
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
